CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
REVENUES:
Net product sales	$ 6,398,227	$ 5,427,427
License and royalty revenue	201,931	100,000
R&D, milestone and grant revenue	1,116,974	797,740
TOTAL REVENUES	7,717,132	6,325,167
COSTS AND EXPENSES:
Cost of product sales	4,117,779	3,219,215
Research and development expenses	1,847,102	2,246,572
Selling, general and administrative expenses	2,406,569	2,488,337
TOTAL OPERATING EXPENSES	8,371,450	7,954,124
LOSS FROM OPERATIONS	(654,318)	(1,628,957)
OTHER INCOME (EXPENSE):
Interest income	5,044	13,382
Interest expense	(3,069)	0
TOTAL OTHER INCOME	1,975	13,382
LOSS BEFORE INCOME TAXES	(652,343)	(1,615,575)
Income tax provision	0	0
NET LOSS	$ (652,343)	$ (1,615,575)
Basic loss per share (in dollars per share)	$ (0.05)	$ (0.13)
Diluted loss per share (in dollars per share)	$ (0.05)	$ (0.13)
Weighted average number of shares outstanding, basic (in shares)	13,267,246	12,270,679
Weighted average number of shares outstanding, diluted (in shares)	13,267,246	12,270,679